CD BioSciences has launched customizable aging mouse models designed to revolutionize preclinical drug development research. By offering gene-editing flexibility and advanced phenotyping capabilities, the company provides researchers with sophisticated tools to investigate age-related diseases and potential therapeutic interventions.
Mouse models represent critical experimental platforms in aging research due to their genetic similarities with humans and ability to simulate complex biological processes. The newly introduced models integrate multiple research approaches, including D-galactose-induced senescence, total body irradiation, and genetically engineered modifications.
The company's approach distinguishes itself through precision-driven customization, leveraging CRISPR-Cas9 technology to create models that accurately represent specific aging pathways and disease mechanisms. By offering a diverse range of mouse strains from C57BL/6 to gene-modified variants, CD BioSciences enables researchers to design experiments tailored to their specific research objectives.
Pharmaceutical and biotechnology researchers stand to benefit significantly from these models, which can potentially compress drug discovery timelines by providing more accurate representations of age-related conditions such as sarcopenia, osteoarthritis, and chronic kidney disease. The models' scalability and compliance with global regulatory standards further enhance their research utility.
CD BioSciences' comprehensive service model extends beyond model creation, offering end-to-end support including biomarker analysis and AI-driven metabolic profiling. This holistic approach aims to expedite research into longevity and age-specific diseases, addressing a critical need in the rapidly evolving field of aging research.
